Spots Global Cancer Trial Database for pazopanib
Every month we try and update this database with for pazopanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | NCT00732420 | Solid Tumours | topotecan pazopanib | 18 Years - | GlaxoSmithKline | |
| pazopanib_NCRCC,Ph2 STUDY | NCT01538238 | Locally Advance... | pazopanib | 19 Years - | Samsung Medical Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | NCT01238770 | Epithelial Ovar... | Pazopanib | 18 Years - | University Hospital Heidelberg | |
| Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma | NCT02555748 | Metastatic Rena... | Pazopanib Sunitinib | 18 Years - | Institut Claudius Regaud | |
| VEG111485: A QTc Study of Pazopanib | NCT00861029 | Carcinoma, Rena... | Pazopanib Placebo for paz... Moxifloxacin Placebo for mox... | 18 Years - | GlaxoSmithKline | |
| Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | NCT01391611 | Gastrointestina... | Pazopanib | 18 Years - | Stanford University | |
| Combined Modality Treatment of Sarcomas of the Extremities | NCT01985295 | Sarcoma,Soft Ti... | pazopanib | 18 Years - | The Netherlands Cancer Institute | |
| VEG111485: A QTc Study of Pazopanib | NCT00861029 | Carcinoma, Rena... | Pazopanib Placebo for paz... Moxifloxacin Placebo for mox... | 18 Years - | GlaxoSmithKline | |
| Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT01377298 | Head and Neck S... | Pazopanib | 18 Years - 70 Years | National Taiwan University Hospital | |
| Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | NCT01012362 | Breast Cancer Lung Cancer Colon Cancer Pancreatic Canc... Head and Neck C... Kidney Cancer Sarcoma Hepatocellular ... | Pazopanib Ixabepilone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Pazopanib, Docetaxel, Prednisone Prostate | NCT01385228 | Prostate Cancer | Pazopanib Docetaxel Pazopanib Prednisone Pegfilgrastim | 18 Years - | Duke University | |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | NCT01610206 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Gemcitabine pazopanib | 18 Years - | University of Virginia | |
| Pazopanib in Second-line Therapy in Renal Cell Carcinoma | NCT01577784 | Metastatic Rena... | Pazopanib | 18 Years - | Associació per a la Recerca Oncologica, Spain | |
| Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors | NCT01700699 | Differentiated ... | - | University of Salerno | ||
| A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | NCT06263231 | Sarcoma,Soft Ti... | INT230-6 Eribulin Trabectedin Pazopanib | 18 Years - | Intensity Therapeutics, Inc. | |
| Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma | NCT01813136 | Thyroid Carcino... | Continuous pazo... Intermittent pa... | 18 Years - | Centre Leon Berard | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Combined Modality Treatment of Sarcomas of the Extremities | NCT01985295 | Sarcoma,Soft Ti... | pazopanib | 18 Years - | The Netherlands Cancer Institute | |
| pazopanib_NCRCC,Ph2 STUDY | NCT01538238 | Locally Advance... | pazopanib | 19 Years - | Samsung Medical Center | |
| Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients | NCT02324803 | Self Efficacy Adverse Drug Ev... Carcinoma, Rena... | pazopanib | 18 Years - | Southern China Urology Cancer Consortium | |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | NCT01035658 | Ovarian Cancer Fallopian Tube ... Peritoneal Carc... | Pazopanib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients | NCT02575066 | Sarcoma Soft Tissue Sar... | external beam r... pazopanib | 18 Years - | The Netherlands Cancer Institute | |
| Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | NCT03628131 | Relapsed Pediat... Refractory Pedi... | Pazopanib Ifosfamide Carboplatin Etoposide | 2 Years - 22 Years | Samsung Medical Center | |
| Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma | NCT01330966 | Chondrosarcoma Metastatic Chon... | pazopanib | 18 Years - | George Clinical Pty Ltd | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | NCT02300545 | Sarcoma, Soft T... Soft Tissue Sar... | Pazopanib | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | NCT01472081 | Renal Cell Carc... Clear-cell Meta... | Nivolumab Pazopanib Sunitinib Ipilimumab | 18 Years - | Bristol-Myers Squibb | |
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | NCT01147822 | Carcinoma, Rena... | Pazopanib Sunitinib | 18 Years - | Novartis | |
| Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib | NCT03735758 | Soft Tissue Sar... | pazopanib or gu... | 18 Years - | GWT-TUD GmbH | |
| Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy | NCT00753688 | Sarcoma, Soft T... | PAZOPANIB Placebo | 18 Years - | GlaxoSmithKline | |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib | NCT01514448 | Metastatic Rena... | Everolimus (RAD... | 18 Years - | Novartis | |
| Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor | NCT01099540 | Neuroendocrine ... | Pazopanib | 18 Years - | Samsung Medical Center | |
| Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer | NCT01644825 | Ovarian Cancer | paclitaxel pazopanib | 18 Years - 75 Years | National Cancer Institute, Naples | |
| Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | NCT01238770 | Epithelial Ovar... | Pazopanib | 18 Years - | University Hospital Heidelberg | |
| FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer | NCT01503372 | Advanced Gastri... | Pazopanib 5-FU, Oxaliplat... | 18 Years - | Charite University, Berlin, Germany | |
| Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma | NCT02393820 | Salivary Gland ... | pazopanib | 18 Years - | UNICANCER | |
| An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | NCT00992121 | Carcinoma, Rena... | Bevacizumab Pazopanib 2 wee... Pazopanib 3 wee... | 18 Years - | GlaxoSmithKline | |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) | NCT01323400 | GIST | Pazopanib Best supportive... | 18 Years - 90 Years | Centre Leon Berard | |
| HYPAZ: Hypertension Induced by Pazopanib | NCT01392352 | Renal Cell Carc... Soft Tissue Sar... Glioblastoma Ovarian Cancer Cervical Cancer Breast Cancer Non-small Cell ... Small Cell Lung... Pancreatic Canc... Melanoma Gastrointestina... | Pazopanib | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | NCT02729194 | Carcinoma, Rena... | Pazopanib Low Fat Diet | 18 Years - | University of Michigan Rogel Cancer Center | |
| Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS | NCT01995981 | Sarcoma, Soft T... | Pazopanib | 18 Years - | Radboud University Medical Center | |
| A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies | NCT01542047 | Cancer, Metasta... | Carboplatin Pazopanib | 18 Years - | New Mexico Cancer Care Alliance | |
| Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02331498 | Glioblastoma Mu... | Pazopanib | 18 Years - 70 Years | Centre Antoine Lacassagne | |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | NCT02307474 | Clear Cell Rena... Renal Cell Carc... | Stereotactic Ra... Pazopanib Hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib | NCT03735758 | Soft Tissue Sar... | pazopanib or gu... | 18 Years - | GWT-TUD GmbH | |
| Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | NCT01184326 | Solid Tumor Kidney Cancer | pazopanib everolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | NCT01636908 | Cancer Advanced Solid ... | Sunitinib Sorafenib Erlotinib Everolimus Lapatinib Dasatinib Pazopanib Vemurafenib tumor biopsy skin biopsy (op... | 18 Years - | Amsterdam UMC, location VUmc | |
| A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer | NCT02960906 | Clear Cell Meta... | Nivolumab Ipilimumab Pazopanib Sunitinib | 18 Years - | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer | NCT01716546 | Gastric Cancer | Pazopanib | 20 Years - 70 Years | Hellenic Oncology Research Group | |
| Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC) | NCT00749320 | Renal Cell Carc... | Arterial Spin L... | 18 Years - | Dana-Farber Cancer Institute | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer | NCT02383251 | Ovarian Cancer | Pazopanib Paclitaxel | 18 Years - 95 Years | ARCAGY/ GINECO GROUP | |
| Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | NCT02014636 | Carcinoma, Rena... | Pazopanib MK-3475 | 18 Years - | Novartis | |
| Pazopanib for Treating Uterine Leiomyosarcoma | NCT02378142 | Uterine Leiomyo... | Pazopanib | 18 Years - | GOG Foundation | |
| Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018) | NCT02014636 | Carcinoma, Rena... | Pazopanib MK-3475 | 18 Years - | Novartis | |
| Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors | NCT02691767 | Refractory Soli... | pazopanib | 19 Years - | Samsung Medical Center | |
| Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors | NCT02450136 | Refractory Soli... | pazopanib | 20 Years - | Samsung Medical Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer | NCT01080248 | Pancreatic Canc... | Gemcitabine Pazopanib | 18 Years - | Washington University School of Medicine | |
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors | NCT01956669 | Solid Tumours | Pazopanib | 1 Year - 18 Years | Novartis | |
| Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | NCT01391611 | Gastrointestina... | Pazopanib | 18 Years - | Stanford University | |
| Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | NCT01227928 | Neoplasms, Ovar... | Pazopanib Placebo compara... | 18 Years - | GlaxoSmithKline | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients | NCT02575066 | Sarcoma Soft Tissue Sar... | external beam r... pazopanib | 18 Years - | The Netherlands Cancer Institute | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | NCT01582204 | Renal Cancer | 124IcG250 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | NCT03149120 | Soft Tissue Sar... | Nivolumab Pazopanib | 18 Years - 100 Years | NYU Langone Health | |
| Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer | NCT04823923 | Kidney Neoplasm | blood sampling ... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors | NCT00800345 | Gynecologic Tum... | Oral Topotecan Pazopanib | 18 Years - | Vector Oncology | |
| Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer | NCT00367679 | Non-Small Cell ... Lung Cancer, No... | Pazopanib | 21 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
